STX4 and type 2 diabetes mellitus: Marked reduction in STX4 protein in the T2D donor islets (~70% reduction) and significant improvement of GSIS in otherwise secretion-deficient T2D islets following STX4 replenishment holds the key to the therapeutic potential of STX4 in diabetes treatment [20].